Cargando...
Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...
Gardado en:
| Publicado en: | Brain Sci |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7692182/ https://ncbi.nlm.nih.gov/pubmed/33143271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci10110802 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|